Tenofovir alafenamide and weight: What do we still need to know to inform clinical decisions?
- PMID: 37096332
- DOI: 10.1111/hiv.13497
Tenofovir alafenamide and weight: What do we still need to know to inform clinical decisions?
Comment on
-
Weight gain following the single substitution of tenofovir disoproxil fumarate by tenofovir alafenamide in HIV-infected people from the French Dat'AIDS cohort: A propensity score-matched analysis.HIV Med. 2023 Aug;24(8):925-932. doi: 10.1111/hiv.13488. Epub 2023 Apr 4. HIV Med. 2023. PMID: 37015896
References
REFERENCES
-
- Podany AT, Bares SH, Havens J, et al. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. Aids. 2018;32(6):761-765.
-
- Surial B, Cavassini M, Calmy A, et al. Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort. BMC Infect Dis. 2019;19(1):834.
-
- Surial B, Mugglin C, Calmy A, et al. Weight and metabolic changes after switching from Tenofovir Disoproxil fumarate to Tenofovir Alafenamide in people living with HIV: a cohort study. Ann Intern Med. 2021;174(6):758-767.
-
- Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of Tenofovir to treat HIV. N Engl J Med. 2019;381(9):803-815.
-
- Hocqueloux L, Menard A, Arvieux C, et al. Weight gain following the single substitution of tenofovir disoproxil fumarate by tenofovir alafenamide in HIV-infected people from the French Dat'AIDS cohort: A propensity score-matched analysis. HIV Med. 2023;24(8):925-932.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical